Buspirone augmentation of fluoxetine in obsessive-compulsive disorder



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via HighWire
	Citing Articles via Google Scholar



	Articles by Markovitz, P. J.
	Articles by Calabrese, J. R.
	Search for Related Content



	PubMed Citation
	Articles by Markovitz, P. J.
	Articles by Calabrese, J. R.

Am J Psychiatry 1990; 147:798-800
Copyright © 1990 by American Psychiatric Association

REGULAR ARTICLES

Buspirone augmentation of fluoxetine in obsessive-compulsive disorder

PJ Markovitz, SJ Stagno and JR Calabrese
Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH.

Eleven obsessive-compulsive patients underwent a prospective open-label trial of fluoxetine monotherapy followed by buspirone augmentation. The combination therapy was statistically superior to fluoxetine monotherapy. The results point to the importance of the 5-HT1a receptor in obsessive-compulsive disorder.

This article has been cited by other articles:

J.F.W. Deakin
A review of clinical efficacy of 5-HT 1A agonists in anxiety and depression
J Psychopharmacol, January 1, 1993; 7(3): 283 - 289.
[PDF]

M. A. Jenike
Geriatric Obsessive-Compulsive Disorder
J Geriatr Psychiatry Neurol, January 1, 1991; 4(1): 34 - 39.
[PDF]

Get information about faster international access.